Novavax (NVAX) stock Forecast for 2021 – 2025

Novavax (NVAX) stock Forecast for 2022 – 2026

Last update: 05-28-2022, 12:20

Sector: Healthcare

The share price of Novavax, Inc. (NVAX) now

What analysts predict:: $158.67

52-week high/low: $277.8 / $41.33

50/200 Day Moving Average: $61.76 / $138.18

This figure corresponds to the average price over the previous 50/200 days. For Novavax stocks, the 50-day moving average is the resistance level today.

For Novavax stocks, the 200-day moving average is the resistance level today.

Are you interested in Novavax, Inc. stocks and want to buy them, or are they already in your portfolio? If yes, then on this page you will find useful information about the dynamics of the Novavax stock price in 2022, 2023, 2024, 2025, 2026. How much will one Novavax share be worth in 2022 - 2026?

When should I take profit in Novavax stock? When should I record a loss on Novavax stock? What are analysts' forecasts for Novavax stock? What is the future of Novavax stock?

We forecast Novavax stock performance using neural networks based on historical data on Novavax stocks. Also, when forecasting, technical analysis tools are used, world geopolitical and news factors are taken into account.

Novavax stock prediction results are shown below and presented in the form of graphs, tables and text information, divided into time intervals. (Next month, 2022, 2023, 2024, 2025 and 2026)

The final quotes of the instrument at the close of the previous trading day are a signal to adjust the forecasts for Novavax shares. This happens once a day.




Historical and forecast chart of Novavax stock

The chart below shows the historical price of Novavax stock and a prediction chart for the next month. For convenience, prices are divided by color. Forecast prices include: Optimistic Forecast, Pessimistic Forecast, and Weighted Average Best Forecast. Detailed values for the Novavax stock price can be found in the table below.

Long-term forecasts by years.

Novavax daily forecast for a month

Date Target Pes. Opt. Vol., %
May 30 59.54 57.88 63.78 10.18
May 31 60.46 56.10 62.58 11.54
Jun 01 58.17 56.50 60.21 6.58
Jun 02 60.16 57.56 63.08 9.59
Jun 03 64.33 61.43 66.99 9.05
Jun 04 63.92 60.76 67.95 11.84
Jun 05 63.52 60.72 64.84 6.78
Jun 06 62.78 58.99 63.91 8.33
Jun 07 58.88 55.81 61.00 9.31
Jun 08 59.36 56.31 62.51 11.00
Jun 09 61.49 58.67 63.49 8.21
Jun 10 63.21 59.28 65.94 11.23
Jun 11 65.26 63.85 66.84 4.69
Jun 12 70.25 65.57 74.74 13.98
Jun 13 68.29 63.56 71.48 12.47
Jun 14 66.63 63.51 69.63 9.63
Jun 15 72.33 69.66 75.13 7.85
Jun 16 73.50 70.92 76.81 8.30
Jun 17 75.48 70.32 79.97 13.72
Jun 18 77.59 72.14 80.87 12.10
Jun 19 74.79 71.23 77.62 8.98
Jun 20 72.37 70.87 77.13 8.82
Jun 21 76.02 72.32 79.30 9.65
Jun 22 79.17 75.89 82.94 9.29
Jun 23 78.67 73.43 81.50 10.99
Jun 24 77.32 74.96 82.47 10.03
Jun 25 73.08 71.56 74.98 4.78
Jun 26 71.30 68.54 74.25 8.33
Jun 27 70.92 68.75 73.60 7.06
Jun 28 67.98 63.88 71.65 12.16

Novavax Daily Price Targets


Novavax Stock Forecast 05-30-2022.

Forecast target price for 05-30-2022: $59.54. Positive dynamics for Novavax shares will prevail with possible volatility of 9.243%.

Pessimistic target level: 57.88

Optimistic target level: 63.78


Novavax Stock Forecast 05-31-2022.

Forecast target price for 05-31-2022: $60.46. Positive dynamics for Novavax shares will prevail with possible volatility of 10.347%.

Pessimistic target level: 56.10

Optimistic target level: 62.58


Novavax Stock Forecast 06-01-2022.

Forecast target price for 06-01-2022: $58.17. Negative dynamics for Novavax shares will prevail with possible volatility of 6.173%.

Pessimistic target level: 56.50

Optimistic target level: 60.21


Novavax Stock Forecast 06-02-2022.

Forecast target price for 06-02-2022: $60.16. Positive dynamics for Novavax shares will prevail with possible volatility of 8.754%.

Pessimistic target level: 57.56

Optimistic target level: 63.08


Novavax Stock Forecast 06-03-2022.

Forecast target price for 06-03-2022: $64.33. Positive dynamics for Novavax shares will prevail with possible volatility of 8.297%.

Pessimistic target level: 61.43

Optimistic target level: 66.99


Novavax Stock Forecast 06-04-2022.

Forecast target price for 06-04-2022: $63.92. Negative dynamics for Novavax shares will prevail with possible volatility of 10.583%.

Pessimistic target level: 60.76

Optimistic target level: 67.95


NVAX (NVAX) Monthly Stock Prediction for 2022

Month Target Pes. Opt. Vol., %
Jun. 51.39 48.15 54.78 12.10
Jul. 50.00 43.55 60.35 27.84
Aug. 44.00 40.44 52.19 22.51
Sep. 33.57 29.34 40.22 27.05
Oct. 32.57 29.34 36.77 20.19
Nov. 35.69 32.80 43.62 24.80
Dec. 36.76 29.59 43.49 31.95

Novavax forecast for this year


Novavax Stock Prediction for Jun 2022

An downtrend is forecast for this month with an optimal target price of $51.3888. Pessimistic: $48.15. Optimistic: $54.78


Novavax Stock Prediction for Jul 2022

An downtrend is forecast for this month with an optimal target price of $50.0013. Pessimistic: $43.55. Optimistic: $60.35


Novavax Stock Prediction for Aug 2022

An downtrend is forecast for this month with an optimal target price of $44.0012. Pessimistic: $40.44. Optimistic: $52.19


Novavax Stock Prediction for Sep 2022

An downtrend is forecast for this month with an optimal target price of $33.5729. Pessimistic: $29.34. Optimistic: $40.22


Novavax Stock Prediction for Oct 2022

An downtrend is forecast for this month with an optimal target price of $32.5657. Pessimistic: $29.34. Optimistic: $36.77


Novavax Stock Prediction for Nov 2022

An uptrend is forecast for this month with an optimal target price of $35.692. Pessimistic: $32.80. Optimistic: $43.62


Novavax Stock Prediction for Dec 2022

An uptrend is forecast for this month with an optimal target price of $36.7628. Pessimistic: $29.59. Optimistic: $43.49




Novavax (NVAX) Monthly Stock Prediction for 2023

Month Target Pes. Opt. Vol., %
Jan 34.01 26.25 36.66 28.39
Feb 31.76 24.61 38.62 36.27
Mar 36.81 32.06 41.67 23.06
Apr 33.50 30.08 39.53 23.90
May 38.32 33.84 46.71 27.56
Jun 47.40 43.00 52.81 18.58
Jul 43.85 38.72 53.19 27.21
Aug 54.24 41.71 66.93 37.68
Sep 60.26 53.21 71.29 25.36
Oct 53.21 41.40 62.31 33.56
Nov 52.41 45.18 57.92 21.99
Dec 49.74 43.92 53.17 17.40

Novavax (NVAX) Monthly Stock Prediction for 2024

Month Target Pes. Opt. Vol., %
Jan 37.80 30.66 41.66 26.41
Feb 30.09 24.22 35.87 32.47
Mar 27.02 24.35 32.61 25.35
Apr 22.40 18.97 25.36 25.18
May 20.32 17.51 24.95 29.80
Jun 18.55 15.43 22.67 31.92
Jul 16.60 14.66 17.65 16.93
Aug 20.49 18.21 21.84 16.60
Sep 18.95 15.43 22.99 32.89
Oct 16.85 15.28 18.87 19.02
Nov 17.10 15.71 18.28 14.03
Dec 15.20 12.15 16.11 24.62



Novavax (NVAX) Monthly Stock Prediction for 2025

Month Target Pes. Opt. Vol., %
Jan 13.20 12.25 15.29 19.93
Feb 15.61 13.50 16.69 19.08
Mar 19.54 16.14 22.65 28.73
Apr 17.96 14.24 20.39 30.13
May 21.46 18.05 25.78 29.97
Jun 20.43 16.26 23.07 29.50
Jul 22.33 20.32 24.88 18.31
Aug 25.35 21.17 30.67 30.99
Sep 23.75 18.76 27.24 31.12
Oct 18.41 15.15 19.90 23.87
Nov 15.81 13.53 16.90 19.92
Dec 14.82 12.50 18.06 30.76

Novavax (NVAX) Monthly Stock Prediction for 2026

Month Target Pes. Opt. Vol., %
Jan 15.57 13.38 16.60 19.42
Feb 19.82 18.34 22.50 18.50
Mar 18.81 16.05 20.90 23.22
Apr 24.28 19.48 25.74 24.34
May 30.26 25.27 34.53 26.82
Jun 35.25 30.28 43.61 30.56
Jul 35.25 26.90 42.65 36.94
Aug 33.77 26.38 37.01 28.74
Sep 30.33 27.51 37.06 25.78
Oct 33.42 29.21 39.44 25.93
Nov 36.53 34.12 41.90 18.57
Dec 39.05 32.49 47.25 31.24

Novavax information and performance

Novavex, Inc. Together with its subsidiary Novavax AB, a late-stage biotechnology company, it discovers, develops and commercializes vaccines to prevent serious infectious diseases. The company’s leading vaccine candidates include ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate, which is in stage III clinical trials to protect infants from RSV disease through maternal immunization; and NanoFlu, which is in phase III clinical trials for the treatment of seasonal influenza in the elderly. Its leading adjuvant is Matrix-M, which is used to enable the vaccine to enhance the amplitude of the immune response and qualitatively change it, and to allow the immune system to attack microorganisms, and also to allow immunization with much smaller doses of antigen. The company is also developing the RSV F vaccine for the elderly (60 years and older), which is in phase II clinical trials, as well as for healthy children aged six months to five years, who are in phase I clinical trials. In addition, it is developing candidate nanoparticle vaccines for clinical trials against the Ebola virus, which is in clinical trials stage I; and a combined respiratory vaccine to protect against influenza and RSV. In addition, the company is developing a COVID-19 vaccine against the pneumonia-like coronavirus, which is in the preclinical stage. Novavex, Inc. the company was founded in 1987 and is headquartered in Gaithersburg, Maryland.

Novavax Address

20 FIRSTFIELD ROAD, GAITHERSBURG, MD, US

Market Capitalization: 4 016 119 000 $

Market capitalization is the total market value of all issued shares of a company. It is calculated by the formula multiplying the number of shares in the company outstanding by the market price of one share.

EBITDA: -157 414 000 $

EBITDA is earnings before interest, income tax and depreciation of assets.

PE Ratio: None

P/E ratio (price to earnings) - shows the ratio between the price of a share and the company's profit

PEG Ratio: N/A

Price/earnings to growth

DPS: N/A

Dividend Per Share is a financial indicator equal to the ratio of the company's net profit available for distribution to the annual average of ordinary shares.

DY: N/A

Dividend yield is a ratio that shows how much a company pays in dividends each year at the stock price.

EPS: -17.51

EPS shows how much of the net profit is accounted for by the common share.

Quarterly Earnings Growth YOY: N/A

Quarterly Revenue Growth YOY: 0.574

Trailing PE: -

Trailing P/E depends on what has already been done. It uses the current share price and divides it by the total earnings per share for the last 12 months.

Forward PE: 1.502

Forward P/E uses projections of future earnings instead of final numbers.

EV To Revenue: 1.68

Enterprise Value (EV) /Revenue

EV To EBITDA: -

The EV / EBITDA ratio shows the ratio of the cost (EV) to its profit before tax, interest and amortization (EBITDA).

Shares Outstanding: 78135000

Number of issued ordinary shares

Shares Float: N/A

Number of freely tradable shares

Shares Short Prior Month: N/A

Shares Short Prior Month - the number of shares in short positions in the last month.

Short Ratio: N/A

Percent Insiders: N/A

Percent Institutions: N/A


Novavax (NVAX) stock dividend

Novavax last paid dividends on 01/01/1970. The next scheduled payment will be on 05/10/2019. The amount of dividends is $0 per share. If the date of the next dividend payment has not been updated, it means that the issuer has not yet announced the exact payment. As soon as information becomes available, we will immediately update the data. Bookmark our portal to stay updated.

Last Split Factor:

Last Split Date: 01/01/1970

Splitting of shares is an increase in the number of securities of the issuing company circulating on the market due to a decrease in their value at constant capitalization.

For example, a 5: 1 ratio means that the value of one share will decrease 5 times, the total amount will increase 5 times. It is important to understand that this procedure does not change the capitalization of the company, as well as the total value of assets held in private hands.




Related stocks from Healthcare sector


Disclaimer:

All forecast data on the site are provided for informational purposes of using neural forecasting tools in the financial market and are not a call to action and, moreover, are not trading signals. When using the forecast data, the investor assumes all financial risks. The pandaforecast.com portal is not responsible for the loss of your money in the stock market as a result of using the information contained on the site.